Evidence map›Paper›PMID 31226165›Full record

ArticlePloS one2019

Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?

Kayla Stankevitz, Katie Schwartz, Theresa Hoke, Yixuan Li, Michele Lanham, Imelda Mahaka, Saiqa Mullick

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Kayla StankevitzFHI 360, Durham, NC, United States of America.ORCID 0000-0002-9779-7014
Katie SchwartzFHI 360, Durham, NC, United States of America.
Theresa HokeFHI 360, Durham, NC, United States of America.
Yixuan LiFHI 360, Durham, NC, United States of America.
Michele LanhamFHI 360, Durham, NC, United States of America.ORCID 0000-0003-3012-5683
Imelda MahakaPangaea Zimbabwe AIDS Trust, Harare, Zimbabwe.
Saiqa MullickWits RHI, Johannesburg, South Africa.
Family Health International 360 · USFamily Aids Caring Trust · ZW

Funding

PEPFAR
6 · The paper itself

Abstract

introductionARV-based pre-exposure prophylaxis (PrEP) has the potential to avert many new HIV infections, yet little is known about how to reach women at high risk for HIV infection and motivate them to initiate PrEP. Clinical trials have succeeded in recruiting at-risk participants, evidenced by control arm HIV incidence ≥3% (defined by the World Health Organization as "substantial risk"). We examined experiences from HIV prevention trials to document recruitment strategies and identify practical, potentially effective strategies for reaching women in real-world PrEP delivery.

methodsWe conducted semi-structured qualitative phone interviews with 31 staff from five countries who had worked on one or more of seven ARV-based HIV prevention clinical trials. Questions explored recruitment strategies used to reach women at risk of HIV and to successfully communicate about PrEP (inclusive of oral and vaginal formulations). We structurally coded data in NVivo and analyzed codes to derive themes. We conducted results interpretation webinars with research and programmatic stakeholders to validate findings and develop recommendations.

resultsClinical trial researchers employed a range of recruitment strategies to recruit at-risk women. They recommended engaging the local community and potential PrEP users via community events, meetings with gatekeepers, and use of community advisory boards; and they encouraged interpersonal communication like presentations in waiting rooms and door-to-door recruitment to address personal concerns and prevent misinformation. Participants also stressed the importance of addressing the challenges that already exist within the health system to create a more enabling environment and delivering positive messages through a variety of communication channels to normalize PrEP.

conclusionsFindings from this study provide important insights into potentially effective ways for countries currently rolling out oral PrEP to reach at-risk women with information about PrEP and promote uptake.

Indexed as

Clinical Trials as TopicPatient SelectionAdultAfrica South of the SaharaAnti-HIV AgentsAnti-Retroviral AgentsFemaleHIV InfectionsHumansInterviews as TopicPre-Exposure ProphylaxisRetrospective StudiesRisk FactorsYoung AdultAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

PMID31226165
PMCPMC6588242
OpenAlexW2949464077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.